Categories AlphaGraphs, Earnings, Technology
Earnings Infographic: Highlights of Weibo’s Q4 2022 results
Weibo Corporation (NASDAQ: WB) has reported a decline in revenues and adjusted earnings for the fourth quarter of 2022, amid muted user growth.

The China-based social networking company reported an adjusted profit of $0.75 per share for the most recent quarter, down 10% from the year-ago period. On an unadjusted basis, net income was $141.9 million or $0.60 per share, compared to $115.7 million or $0.50 per share last year.
Adjusted profit was hurt by a 27% decrease in revenues to $448 million. At the end of the quarter, Weibo had around 586 million monthly active users and 252 million daily active users.
Check this space to read management/analysts’ comments on quarterly reports
“Our community remained healthy and engaged, mainly attributable to the optimization of social product and effective channel investment. On monetization, our advertising business has exhibited recovery trend in the second half of 2022, although macro challenges continuously weighed on the overall advertising demand,” said Weibo’s CEO Gaofei Wang.
Prior Performance
_________________________________________________________________________________________________________________
Stocks you may like:
International Business Machines Corp. (IBM) Stock
_________________________________________________________________________________________________________________
Most Popular
DIS Earnings: All you need to know about Walt Disney’s Q4 2025 earnings results
The Walt Disney Company (NYSE: DIS) reported its fourth quarter 2025 earnings results today. Revenues of $22.5 billion were comparable to the year-ago quarter. Net income attributable to The Walt
Cisco (CSCO) reports higher Q1 revenue and earnings; results beat estimates
Network gear maker Cisco Systems Inc. (NASDAQ: CSCO) on Wednesday announced financial results for the first quarter of fiscal 2026, reporting higher revenue and profit. Earnings, on an adjusted basis,
Advantage of CERo’s CER receptor lies in native human protein-based antigen binding: CEO
CERo Therapeutics Holdings, Inc. is a biotechnology company pioneering engineered T cell immunotherapies to combat cancer, with a focus on hematologic malignancies and solid tumors. In an email conversation with


